Pharma Stock Jumps 5% After Signing $12 Million Deal to Expand Its Business in Africa

Synopsis:- Shares rose 5% after a USD 12 million Africa-focused deal, expanding presence across Ghana, Nigeria, and Kenya. The move could place it among the top five regional players, while improving margins, operating efficiency, and positioning in high-growth emerging markets.

The shares of the prominent pharmaceutical company gained up to 5 percent in today’s trading session after the company entered into definitive agreements for the acquisition and in‑licensing of a portfolio.

With a market capitalization of Rs 8,485.42 crore, the shares of Strides Pharma Science Ltd were trading at Rs 920.60 per share, increasing around 5 percent as compared to the previous closing price of Rs 876.25 apiece.

Definitive Agreement

The shares of Strides Pharma Science Ltd have seen positive movement after its step-down subsidiary, Strides Pharma International AG (SPIAG), executed agreements with Sandoz, the company is set to expand in Sub-Saharan Africa across key markets like Ghana, Nigeria, and Kenya. With an upfront USD 12 million payment and royalty-linked payouts, the deal strengthens its branded generics portfolio across major therapeutic segments.

Moreover, the integration of Sandoz’s portfolio with existing operations is expected to enhance scale and market positioning, potentially placing the company among the top five players in the region. The structured agreement, including guarantees and performance-linked royalties, supports disciplined execution, with the transaction expected to close by Q2 FY27.

Commenting on the milestone, Aditya Kumar, Executive Director, Business Development, said the acquisition significantly strengthens the company’s Africa strategy by more than doubling its regional presence. It enhances scale, improves market penetration, and expands reach across retail and hospital channels, aligning with long-term plans to grow Ex-US markets to match the scale of its US business.

Financial Highlights

The company delivered modest revenue growth of 4%, rising from  Rs 1,154 crore to  Rs 1,195 crore. However, profitability improved sharply, with net profit surging 131% from  Rs 90 crore to  Rs 208 crore. This indicates strong margin expansion and better cost efficiency, reflecting improved operational performance despite relatively stable top-line growth.

Over the past year, Strides Pharma Science Ltd has shown steady operational improvement. Operating profit increased from  Rs 210 crore in Dec 2024 to  Rs 236 crore in Dec 2025, indicating better execution. OPM also improved from 18% to 20%, reflecting enhanced efficiency and margin expansion, supported by cost control and improved product mix.

Strides Pharma Science Ltd is a global pharmaceutical company focused on generic formulations, with a strong presence across regulated and emerging markets. The company specializes in niche and complex products, leveraging its manufacturing and R&D capabilities to drive growth while expanding its footprint in key international healthcare markets.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock Jumps 5% After Signing $12 Million Deal to Expand Its Business in Africa appeared first on Trade Brains.